JPWO2023165334A5 - - Google Patents
Info
- Publication number
- JPWO2023165334A5 JPWO2023165334A5 JP2023580943A JP2023580943A JPWO2023165334A5 JP WO2023165334 A5 JPWO2023165334 A5 JP WO2023165334A5 JP 2023580943 A JP2023580943 A JP 2023580943A JP 2023580943 A JP2023580943 A JP 2023580943A JP WO2023165334 A5 JPWO2023165334 A5 JP WO2023165334A5
- Authority
- JP
- Japan
- Prior art keywords
- hcov
- cov
- pharmaceutically acceptable
- sars
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210199543.5 | 2022-03-01 | ||
| CN202210199543 | 2022-03-01 | ||
| PCT/CN2023/076078 WO2023165334A1 (zh) | 2022-03-01 | 2023-02-15 | 酮酰胺类衍生物及其制药用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025507472A JP2025507472A (ja) | 2025-03-21 |
| JP2025507472A5 JP2025507472A5 (https=) | 2025-12-17 |
| JPWO2023165334A5 true JPWO2023165334A5 (https=) | 2025-12-17 |
Family
ID=87830006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580943A Pending JP2025507472A (ja) | 2022-03-01 | 2023-02-15 | ケトアミド系誘導体及びその製薬における使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250064789A1 (https=) |
| EP (1) | EP4488264A4 (https=) |
| JP (1) | JP2025507472A (https=) |
| CN (1) | CN116693447B (https=) |
| WO (1) | WO2023165334A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024525589A (ja) | 2021-07-09 | 2024-07-12 | アリゴス セラピューティクス インコーポレイテッド | 抗ウイルス化合物 |
| EP4488264A4 (en) * | 2022-03-01 | 2026-03-04 | Westvac Biopharma Co Ltd | CETO AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09500087A (ja) * | 1992-06-24 | 1997-01-07 | コーテックス ファーマシューティカルズ インコーポレイテッド | カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法 |
| US5514694A (en) * | 1992-09-21 | 1996-05-07 | Georgia Tech Research Corp | Peptidyl ketoamides |
| JPH08208462A (ja) * | 1994-11-24 | 1996-08-13 | Takeda Chem Ind Ltd | カテプシンｌ阻害剤 |
| US6303579B1 (en) * | 1996-10-31 | 2001-10-16 | Alcon Laboratories, Inc. | Use of calpain inhibitors to treat ocular neural pathology |
| CN1306526A (zh) * | 1998-04-20 | 2001-08-01 | Basf公司 | 具有半胱氨酸蛋白酶抑制作用的新的杂环取代酰胺 |
| AU2002232558A1 (en) * | 2000-12-12 | 2002-06-24 | Corvas International, Inc. | Compounds, compositions and methods for treatment of parasitic infections |
| JP2006503069A (ja) * | 2002-09-25 | 2006-01-26 | ジョージア テック リサーチ コーポレイション | 慢性神経疾患におけるケトアミド阻害剤 |
| US8236798B2 (en) * | 2009-05-07 | 2012-08-07 | Abbott Gmbh & Co. Kg | Carboxamide compounds and their use as calpain inhibitors |
| US8598211B2 (en) * | 2009-12-22 | 2013-12-03 | Abbvie Inc. | Carboxamide compounds and their use as calpain inhibitors IV |
| GB201001070D0 (en) * | 2010-01-22 | 2010-03-10 | St George's Hospital Medical School | Theraputic compounds and their use |
| BR112019006110A2 (pt) * | 2016-09-28 | 2019-09-10 | Blade Therapeutics Inc | moduladores de calpaína e usos terapêuticos dos mesmos |
| CN115698035A (zh) * | 2020-04-10 | 2023-02-03 | 共晶制药公司 | 诺如病毒及冠状病毒复制的抑制剂 |
| PH12022553378A1 (en) * | 2020-06-10 | 2024-03-25 | Univ Leuven Kath | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| CN115960088B (zh) * | 2020-07-31 | 2024-07-26 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
| CN114057702B (zh) * | 2020-07-31 | 2022-09-30 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
| US20240083885A1 (en) * | 2020-12-04 | 2024-03-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for inhibiting m pro protease activity and for preventing and treating sars-cov-2 infection |
| WO2022265577A2 (en) * | 2021-06-15 | 2022-12-22 | Agency For Science, Technology And Research | Coronavirus enzyme modulators, methods of synthesis and uses thereof |
| JP2023000996A (ja) * | 2021-06-18 | 2023-01-04 | ラクオリア創薬株式会社 | プロテアーゼ阻害剤としてのケトアミド誘導体 |
| EP4488264A4 (en) * | 2022-03-01 | 2026-03-04 | Westvac Biopharma Co Ltd | CETO AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE |
-
2023
- 2023-02-15 EP EP23762735.1A patent/EP4488264A4/en active Pending
- 2023-02-15 JP JP2023580943A patent/JP2025507472A/ja active Pending
- 2023-02-15 WO PCT/CN2023/076078 patent/WO2023165334A1/zh not_active Ceased
- 2023-02-15 US US18/723,545 patent/US20250064789A1/en active Pending
- 2023-02-17 CN CN202310131329.0A patent/CN116693447B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023017050A5 (https=) | ||
| ES2356093T3 (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol. | |
| AR013506A1 (es) | Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida | |
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| UY27553A1 (es) | Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| JP2005512995A5 (https=) | ||
| JP2009541443A5 (https=) | ||
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| EA200400664A1 (ru) | Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii | |
| RU2002111657A (ru) | ГЕКСАГИДРОФУРО [2,3-b] ФУРАН-3-ИЛ-N-{3-[(1,3-БЕНЗОДИОКСОЛ-5-ИЛСУЛЬФОНИЛ) (ИЗОБУТИЛ) АМИНО]-1-БЕНЗИЛ-2-ГИДРОКСИПРОПИЛ} КАРБАМАТ КАК ИНГИБИТОР РЕТРОВИРУСНОЙ ПРОТЕАЗЫ | |
| NO341573B1 (no) | Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| BRPI0414347A (pt) | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
| BRPI0413186A (pt) | composição de fexofenadina e processo para preparação da mesma | |
| JP2009517411A5 (https=) | ||
| JPWO2023165334A5 (https=) | ||
| AR087240A2 (es) | Composiciones farmaceuticas que tienen epinastina y pseudoefedrina | |
| JP2008540405A5 (https=) | ||
| AR127966A1 (es) | Formulaciones tópicas de inhibidores de pi3k-delta | |
| CL2025001901A1 (es) | Uso de pridopidina para el tratamiento de la enfermedad de huntington juvenil. | |
| JP2003503453A5 (ja) | ガバペンチンおよびプレガバリンを含む相乗作用組成物 | |
| RU2010147881A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА |